Clinical Trial Update: Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders [Phase 2, Phase 3]

View source ↗

Summary

Trial update on an alternate formulation of aripiprazole for agitation in schizophrenia, covering Phase 2 and Phase 3 with the study status listed as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• aripiprazole (alternate formulation) (aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: COMPLETED